← Eichor
Study identifier: NCT01299168 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Diagnostic and Therapeutic Applications in Microarrays in Organ Transplantation

Condition: Validation Study of Molecular Diagnostic System · Development of Reporting System for Molecular Diagnosis · Incorporate Molecular Diagnosis Into Diagnostic Standards  ·  Sponsor: University of Alberta

PhaseN/A
Planned participants500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The current standard for biopsy-based diagnoses of dysfunction of kidney transplants is the Banff Classification which represents arbitrary international consensus. Recent data-driven approaches using molecular and conventional technologies indicate that mere consensus produces frequently incorrect diagnoses with potential harm to patients due to inappropriate treatment. To address this unmet need and improve diagnostics in the area of organ transplantation, the Alberta Transplant Applied Genomics Centre (ATAGC) has developed a new diagnostic system that combines the molecular and histopathological features of transplant biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. The present study will validate and refine this system in 500 prospectively unselected biopsies for clinical indications from American, Canadian and European centres in addition to 300 biopsies already collected. Due to a considerable interest and support from participating Centers, the study is further extended to 1500 prospective biopsies. Thus this is the extension of the INTERCOM study (INTERCOMEX). In addition to demonstrating the feasibility and value of this System in routine patient care and clinical trials, the study will develop and optimize a transparent and user-friendly reporting format to communicate this information to clinicians and obtain detailed feedback on how this system can best improve patient care.

This description comes directly from the study's public registry record.

Talk to the study team

Philip F Halloran, MD PhD  ·  1 780 492-6160  ·  phallora@ualberta.ca

Konrad S Famulski, PhD DSc  ·  1 780 4921725  ·  konrad@ualberta.ca

Always discuss trial participation with your own doctor first.

Locations (26)

University of AlabamaBirmingham, Alabama, United StatesCompleted
University of Maryland School of MedicineBaltimore, Maryland, United StatesCompleted
University of Michigan Health SystemAnn Arbor, Michigan, United StatesCompleted
University of MinnesotaMinneapolis, Minnesota, United StatesCompleted
Barnes-Jewish HospitalSt Louis, Missouri, United StatesCompleted
Montefiore Medical CenterThe Bronx, New York, United StatesCompleted
Pinnacle Transplant AssociatesHarrisburg, Pennsylvania, United StatesCompleted
Texas Transplant Institute - Methodist Healthcare SystemSan Antonio, Texas, United StatesCompleted
Virginia Commonwealth University School of MedicineRichmond, Virginia, United StatesCompleted
University of Wisconsin School of Medicine and Public HealthMadison, Wisconsin, United StatesCompleted
Medical University of ViennaVienna, AustriaRecruiting
Department of Medicine, University of AlbertaEdmonton, Alberta, CanadaRecruiting

+ 14 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01299168